All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Iland, Harry; Bradstock, Ken; G. Supple, Shane; Catalano, Alberto; Collins, Marnie; Hertzberg, Mark; Browett, Peter; Grigg, Andrew; Firkin, Frank; Hugman, Amanda; Reynolds, John; Di Iulio, Juliana; Tiley, Campbell; Taylor, Kerry; Filshie, Robin; Seldon, Michael; Taper, John; Szer, Jeff; J. Moore, John; Bashford, John; F. Seymour, John

doi:10.1182/blood-2012-02-410746

Public

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Published in Blood • Jun 21, 2012

Authors:

Harry Iland

Ken Bradstock

Shane G. Supple

Abstract

The treatment of acute promyelocytic leukemia has improved considerably after recognition of the effectiveness of all-trans-retinoic acid (ATRA), anthracycline-based chemotherapy, and arsenic trioxide (ATO). Here we report the use of all 3 agents in combination in an APML4 phase 2 protocol. For indu...

Subject

Idarubicin

Acute promyelocytic leukemia

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!